Recent News

• 02.09.2026 - Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
• 02.05.2026 - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
• 01.15.2026 - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
• 01.07.2026 - Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
• 12.17.2025 - Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
• 12.09.2025 - ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
• 12.09.2025 - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
• 12.09.2025 - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Recent Filings

• 02.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.09.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.06.2026 - EX-99.1 EX-99.1
• 01.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.15.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.07.2026 - EX-99.1 EX-99.1
• 12.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.31.2025 - EX-99.1 EX-99.1